129 related articles for article (PubMed ID: 38537960)
1. Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
Hashimoto K; Kaira K; Imai H; Miura YU; Shiono A; Mouri A; Yamaguchi OU; Kobayashi K; Kagamu H; Kuji I
Anticancer Res; 2024 Apr; 44(4):1541-1551. PubMed ID: 38537960
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
3. Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade.
Hashimoto K; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Yamaguchi O; Kobayashi K; Kagamu H; Kuji I
J Immunother; 2022 Oct; 45(8):349-357. PubMed ID: 35980360
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
5. The correlation between PD-L1 expression and metabolic parameters of
Xu X; Li J; Yang Y; Sang S; Deng S
Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
[TBL] [Abstract][Full Text] [Related]
6. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
8. Tumor metabolic volume by
Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Shiono A; Miura Y; Murayama Y; Kobayashi K; Kagamu H; Kuji I
Sci Rep; 2020 Sep; 10(1):14990. PubMed ID: 32929123
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer.
Yu X; Zhu Y; Wang J; Song X; Zhu L; Men X; Li X; Dai D; Xu W
Nucl Med Commun; 2017 Feb; 38(2):193-200. PubMed ID: 27977537
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of PET/CT in small-cell lung cancer.
Budak E; Yanarateş A; Akgün A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):9-13. PubMed ID: 31865009
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
13. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
15.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of metabolic tumour volume and total lesion glycolysis measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in small cell lung cancer: A systematic review and meta-analysis.
Nie K; Zhang YX; Nie W; Zhu L; Chen YN; Xiao YX; Liu SY; Yu H
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):84-93. PubMed ID: 30230710
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
19. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
